TY  - CONF

T1  - 161 52-Week Laboratory Safety Findings From an Open-Label Extension Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE)

JO  - Abstracts

UR  - https://doi.org/10.1136/archdischild-2021-europaediatrics.161

PY  - 2021/10/11

AU  - Cork MJ

AU  - Lockshin B

AU  - Blauvelt A

AU  - Chen Z

AU  - Khokhar FA

AU  - Bansal A

AU  - Prescilla R

ED  - 

DO  - DOI: 10.1136/archdischild-2021-europaediatrics.161

PB  - BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health

SP  - A68.2

EP  - A69

Y2  - 2025/11/05

ER  -